Search Within

Michael John Mauro

Formats
  1. Meeting Abstract (188)
  2. Journal Article (67)
  3. Review (8)
  4. Correspondence (4)
  5. Research Letter (3)
  6. Book Section (2)
  7. Editorial (2)
  8. Guidelines (2)
Groups
  1. Adult Leukemia (276)
  2. Center for Hematologic Malignancies (276)
  3. Department of Medicine (276)
  4. Hematologic Malignancies, Division of (276)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Raajit Rampal (12)
  2. Ellin Berman (8)
  3. Eytan Stein (8)
  4. Martin Tallman (7)
  5. Amber King (6)
  6. Andriy Derkach (6)

More People

Years
  1. 2025 (7)
  2. 2024 (17)
  3. 2023 (26)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Journal of Clinical Oncology (22)
  4. Haematologica (21)
  5. Leukemia (12)
  6. American Journal of Hematology (8)

More Publications

Publishers
  1. American Society of Hematology (101)
  2. Elsevier Inc. (47)
  3. American Society of Clinical Oncology (22)
  4. Ferrata Storti Foundation (21)
  5. Nature Publishing Group (13)
  6. John Wiley & Sons (8)

More Publishers

Results (276)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health care resource utilization with asciminib and bosutinib among adults with chronic myeloid leukemia in chronic phase previously treated with ≥2 tyrosine kinase inhibitors: Week 48 and week 96 results from ASCEMBL trial
    Meeting Abstract

    Cortes, J. E.; Sasaki, K.; Réa, D.; Mauro, M. J.; Tran, D.; Wang, P.; Jadhav, K.; Di Caprio, L.; Yocolly, A.
    Value in Health (2022)

    Fulltext@MSK | Save
  • Efficacy and safety results from ASCEMBL, a Phase III study of asciminib vs. bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update
    Meeting Abstract

    Réa, D.; Hochhaus, A.; Mauro, M. J.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, W.; Apperley, J. F.; Cortes, J. E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • AIM4CML Trial in progress: A phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without the T315I mutation
    Meeting Abstract

    Levy, M. Y.; Mauro, M. J.; Issa, G. C.; Andorsky, D.; Tomassetti, S.; Broun, E. R.; Maegawa, R.; Deininger, M.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • ASC2ESCALATE trial in progress: A phase 2 single-arm dose escalation study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase (CMLCP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Sasaki, K.; Mauro, M. J.; Levy, M. Y.; Atallah, E. L.; Koller, P.; Maegawa, R.; Damon, A.; Kumar, J.; Khan, M.; Cortes, J. E.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Asciminib provides durable molecular responses in patients with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: Updated efficacy and safety data from a phase I trial
    Meeting Abstract

    Hughes, T. P.; Cortes, J. E.; Réa, D.; Mauro, M. J.; Hochhaus, A.; Kim, D. W.; Sasaki, K.; Lang, F.; Heinrich, M. C.; Breccia, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia from the PACE and OPTIC trials
    Meeting Abstract

    Apperley, J.; Kantarjian, H.; Deininger, M.; Abruzzese, E.; Cortes, J.; Chuah, C.; DeAngelo, D. J.; DiPersio, J.; Hochhaus, A.; Lipton, J. H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CPCML) by baseline BCR::ABL1 level and baseline mutation status in the OPTIC trial
    Meeting Abstract

    Deininger, M.; Apperley, J.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; de Lavallade, H.; Lipton, J.; Lomaia, E.; McCloskey, J.; Maness, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Five-year overall survival analysis using first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase in a prospective observational study (SIMPLICITY)
    Meeting Abstract

    Mauro, M.; Paquette, R.; Hehlmann, R.; Williams, L. A.; Goldberg, S. L.; Michallet, M.; Gambacorti-Passerini, C.; Tang, D.; DeGutis, I. S.; McBride, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A risk model for CML patients with COVID-19: Importance of molecular response in the context of age, comorbidities and country income
    Meeting Abstract

    Radich, J. P.; Kok, C. H.; Chelysheva, E. Y.; Cortes, J. E.; Jiang, Q.; Mauro, M.; Milojkovic, D.; Moiraghi, B.; Nicolini, F. E.; Ongondi, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular Response of ≤10% BCR::ABL1(IS) is predictive of positive outcomes in treatment-resistant patients with chronic phase chronic myeloid leukemia (CP-CML) treated with ponatinib from the phase 2 optic trial
    Meeting Abstract

    Apperley, J. F.; Cortes, J. E.; Jabbour, E.; Hochhaus, A.; Hughes, T.; Chuah, C.; de Lavallade, H.; Deininger, M. W.; Lipton, J. H.; Lomaia, E.; more...
    Blood (2022)

    Fulltext@MSK | Save